From the Simple to the Complex in the Treatment of Chronic Inflammation: Supramolecular Devices Based on Cyclodextrins and Natural/Synthetic Polymer Derivatives

Dear Colleagues,

Cyclodextrins (CDs) are oligosaccharides that are widely used as carrier systems for bioactive compounds due to their ability to form host–guest inclusion complexes. Hundreds of modified CDs are commercially available for use in research and industrial applications when the drugs have a limited bioavailability on the organism. However, only a limited number of modified cyclodextrins are currently used, mainly as pharmaceutical excipients. On the other hand, inflammation is a normal physiologic response that causes injured tissue to heal. An inflammatory process begins when chemical compounds are released from damaged tissue. In response, the white blood cells produce substances that cause the cells to divide and grow to rebuild tissue to help repair the injury. Once the wound heals, the inflammatory process will end.

Chronic inflammation can be caused by infections that do not go away, by abnormal immune reactions to normal tissues, or by conditions such as obesity. In this sense, the several medical studies about chronic inflammation, defined broadly as conditions that last 1 year or more and require ongoing medical attention and/or limit the activities of daily living, show that heart disease, arthritis, cancer, and diabetes are the leading causes of death and disability in the world.

Therefore, we invite researchers to contribute to this Special Issue with their experimental work, molecular modeling studies of active compounds and supramolecular structures, and pharmacological evaluations for the positive and potential treatment of chronic inflammations via the use of CD derivatives that will support the effective administration of the active principles of controlled methods.

Prof. Dr. Eduardo Sobarzo-Sánchez
Dr. Ana María Méndez-Torres
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cyclodextrin
• supramolecular devices
• synthetic and natural polymers
• chronic inflammation
• nanoparticles and drug carriers